From the Departments of Breast Imaging.
Nuclear Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX.
Clin Nucl Med. 2021 Mar 1;46(3):248-249. doi: 10.1097/RLU.0000000000003421.
68Ga-DOTA peptides have revolutionized the imaging of neuroendocrine tumors because the agents are specific to somatostatin receptors. However, other tumors, including breast cancer, have been shown to express somatostatin receptors. We present the case of a 74-year-old woman with primary cardiac paraganglioma, who was found to have 68Ga-DOTATATE activity in the breast on staging PET/CT. Subsequent breast imaging workup and biopsy confirmed primary invasive lobular breast cancer, which was not 18F-FDG-avid on prior FDG PET/CT. Our case is in alignment with prior studies that suggest that 68Ga-DOTA peptides may play a future role in imaging breast cancer patients.
68Ga-DOTA 肽在神经内分泌肿瘤的成像中具有革命性意义,因为这些药物对生长抑素受体具有特异性。然而,其他肿瘤,包括乳腺癌,已经被证明表达生长抑素受体。我们报告了一例 74 岁女性原发性心脏副神经节瘤的病例,该患者在分期 PET/CT 中发现乳房有 68Ga-DOTATATE 活性。随后的乳房影像学检查和活检证实为原发性浸润性小叶乳腺癌,先前的 FDG PET/CT 未见 18F-FDG 摄取。我们的病例与先前的研究一致,这些研究表明 68Ga-DOTA 肽可能在未来对乳腺癌患者的成像中发挥作用。